30 closest matches · ranked by relevance
Generalized Tonic Clonic Seizures
Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…
Seizure Disorder Generalized Tonic Clonic
Primary: Median Percent Change in Primary Generalized Tonic Clonic Seizure Frequency (PGTC) Per 28 Days During the Titration and Maintenance Periods (Combined) Relative to…
Epilepsy, Tonic-Clonic
Primary: Percent Change From Baseline in Weekly Primary Generalized Tonic-clonic (PGTC) Seizure Frequency During the Entire Double-Blind Treatment Phase — 32.1; 75.4 percent…
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase…
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
Epilepsy, Partial Seizures · Epilepsy, Primary Generalized Tonic-Clonic Seizures
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs…
Partial Onset Seizures · Secondarily Generalized Seizures · Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants
Epilepsy
Primary: Change in the Number of Seizure Days With Absence Seizures From the Baseline Phase to the Maintenance Phase — -0.37 number of seizure days
Epilepsy
Primary: Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period — 222 Participants
Epilepsy, Idiopathic Generalized
Primary: Time to First Seizure — 169; 178 Days
Epilepsy · Generalized Tonic-clonic Seizures
Primary: The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week…
Epilepsy With Partial On-set Seizures
Primary: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase — 36; 37 participants
Partial Seizures · Epilepsies, Partial
Primary: Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase — 2.24; 2.33; 2.32; 1.84 ln (seizures per 28 days)…
Epilepsy
Primary: 50 Percent (%) Responder Rate for Partial Onset Seizure With or Without Secondary Generalization — 80.0 percentage of participants
Epilepsy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Visit 1 to the End of Study (Approximately 61 Weeks) — 37 participants
Partial Onset Seizures
Primary: Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel — 63.0 percentage…
Tuberous Sclerosis
Primary: Percent Change From Baseline in 28-day Seizure Frequency Through the End of 12-Week Treatment Period — -16.61 Percent change
Partial Epilepsy · Catamenial Epilepsy
Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]
Epilepsies, Partial
Primary: Number of Treatment-Emergent Adverse Events (AEs) by Severity: Double-blind Treatment — 0; 2; 2; 4 adverse events
Partial Epilepsy
Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — 55.6; 21.5 percent seizure reduction — p=<0.0001
Epilepsy · Seizures
Primary: Number of Participants With Serious Adverse Events (SAEs) — 0; 1; 2 Participants
Partial Seizures
Primary: Proportion of Participants With Response to Treatment — 0.59; 0.59 proportion of participants
Partial Onset Seizures
Primary: Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase — 1.69; 1.15; 1.58 seizures per 24 hours — p=0.4606
Epilepsy · Generalized Tonic-clonic Seizures
Primary: Incidence of Treatment Emergent Adverse Events During the Entire Study Period — 626 Treatment Emergent Adverse Events
Epilepsy
Primary: Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) — 76; 49 events…
Epilepsies, Partial
Primary: Number of Participants With Adverse Events (AE). — 14; 13; 11; 9 Participants
Partial Epilepsy
Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — -24.0; -35.5; -55.0; -55.0 percent change — p=<0.001
Epilepsy
Primary: The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline — -32.7; -35.6 percent change — p=0.240
Childhood Absence Epilepsy · Petit Mal Epilepsy · Epilepsy
Primary: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy — 81; 43; 85 Participants — p=<0.001
Drug Resistant Partial Onset Seizure
Primary: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period — -21.28; -10.25 Percent change — p=0.1788